Onyx Pharmaceuticals — lobbying record — Receipts Report
Client
Lobbying client · LD-2 disclosures
Onyx Pharmaceuticals
District of Columbia
38 filings from 4 registrants · 2010–2015 · latest filed Jan 21, 2016
Reported on its behalf
$1M
every LD-2 on file
Its own filed spend
$390K
lobbying for itself
Fees to outside firms
$610K
across every firm on file
Spend over time
Every filing period on record, as reported. One column per filed period — a period with no column is a period with no filing, not a zero.
Basis · Amendments and terminations supersede the original report for the same registrant, client and period, so a revised quarter is counted once at its latest filed value. Registration-only filings carry no activity money and are excluded from these totals.
Who lobbies for them
Every outside firm that has filed on this client's behalf, by fees reported.
This record groups every filed spelling of the client's name into one entity, so "MERCK & CO., INC." and "MERCK & CO INC" read as the same company. The grouping is the client's normalized name — organizations that file under genuinely different names appear separately. Handle: onyx-pharmaceuticals.
Reading this · LD-2 reports a hired firm's fee and a registrant's reported expenses on separate lines and never both on one filing, so the two lists above are different quantities and are ranked separately rather than against each other. Firm names link to their own record as the firms chapter lands.
BUD
7 filings
$260K on those filings
Medicare/Medicaid
MMM
5 filings
$270K on those filings
Copyright/Patent/Trademark
CPT
1 filing
$80K on those filings
Trade (domestic/foreign)
TRD
1 filing
$80K on those filings
Note · A filing names one to several issue areas and reports a single dollar figure for the period, so the same money appears beside every issue that filing declares. The dollar column is therefore spend on filings that named this issue — it is not a split of the total, and these figures sum above it. Filing counts do not double-count.
112th Congress
TREAT Act
4 filingsthrough 2012
S. 296112th CongressPreserving Access to Life-Saving Medications Act4 filingsthrough 2012
H.R. 3204113th CongressDrug Quality and Security Act3 filingsthrough 2013
S. 959113th CongressPharmaceutical Quality, Security, and Accountability Act3 filingsthrough 2013
S. 3295112th CongressDepartments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 20133 filingsthrough 2012
S. 3187112th CongressFood and Drug Administration Safety and Innovation Act2 filingsthrough 2012
H.R. 1919113th CongressSafeguarding America's Pharmaceuticals Act of 20131 filingthrough 2013
S. 957113th CongressDrug Supply Chain Security Act1 filingthrough 2013
How these are found · Bill references are extracted from the free-text activity description each filing writes, then matched to the Congress in session that filing year. A reference we can't match to a bill on file is still shown, unlinked — we cite what the filing said rather than guess at what it meant. Naming a bill is not a position on it: LD-2 records that a client lobbied on the bill, never which side.
John W HowardWexler | Walker, a Unit of HILL+KNOWLTON Strategies, LLCCovered position: White House EOP; US House; US Senate
4 filingsthrough 2013
J Kevin BrennanFoley Hoag LLPCovered position: Chief of Staff for Rep. Rosa DeLauro2 filingsthrough 2011
Megan Anderson BrooksCavarocchi Ruscio Dennis Associates, L.L.C.1 filingthrough 2015
Covered positions · 4 of 7 lobbyists named on these filings disclosed a prior government post. The text is reproduced exactly as filed.
